PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Non–Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology


Everett E. Vokes; Suresh Senan; Joseph A. Treat; Neill A. Iscoe


Clin Lung Cancer. 2009;10(3):193-198. 

In This Article

Pemetrexed and Non–Small-Cell Lung Cancer

Pemetrexed is approved for the therapy of patients with NSCLC after previous chemotherapy[20] and was recently approved in Europe for first-line treatment of patients with advanced or metastatic NSCLC of other than predominantly squamous cell histology, based on the results of a large randomized trial comparing pemetrexed and cisplatin to gemcitabine and cisplatin.[21]

In contrast to other contemporary cytotoxic regimens used to treat metastatic disease, pemetrexed regimens with cisplatin or carboplatin can be administered at full systemic doses with radical doses of thoracic radiation.[22,23,24,25] Moreover, there is the consistent finding from 3 randomized trials[21,26,27] demonstrating a favorable treatment by histology interaction for pemetrexed in patients with nonsquamous histology. This finding, coupled with the ability to administer full systemic doses of chemotherapy with radiation increases the likelihood of being able to successfully demonstrate improved efficacy of a pemetrexed-based regimen in the treatment of locally advanced NSCLC compared with a contemporary standard of care.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: